ANUH PHARMA LIMITED
ANUHPHR · General/Diversified · NSE
₹81
Current Market Price
Fair Value (DCF)
₹71
Margin of Safety
-12.6%
Updated 1d ago
YieldIQ Score
22/100
Piotroski F-Score
3/9
Economic Moat
Moderate
Confidence
49%
ROE
—
Debt/Equity
0.00
WACC
11.1%
Market Cap
₹816 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
18.8%
Return on capital employed
EV / EBITDA
14.0×
Enterprise multiple
Debt / EBITDA
0.2×
Leverage vs earnings
Interest Coverage
99.4×
EBIT covers interest
Current Ratio
2.11×
Short-term liquidity
Asset Turnover
1.31×
Revenue per ₹ of assets
Revenue CAGR (3Y)
10.8%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹81.38
Bear case
₹43.32
MoS -87.9%
Base case
₹71.1
MoS -14.5%
Bull case
₹89.42
MoS +9.0%
Ratio Trends
ANUHPHR · last 4 annual periods
ROE
14.5%
ROCE
20.9%
Operating Margin
—
Debt / Equity
0.03×
PE
—
EV / EBITDA
—
Historical Financials
ANUHPHR · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹487 Cr | ₹527 Cr | ₹647 Cr | ₹662 Cr | +10.8% |
| EBITDA | ₹52.0 Cr | ₹57.4 Cr | ₹87.2 Cr | ₹70.4 Cr | +10.6% |
| EBIT | — | — | — | — | — |
| PAT | ₹30.6 Cr | ₹36.2 Cr | ₹60.1 Cr | ₹47.4 Cr | +15.7% |
| EPS (diluted) | — | — | — | — | — |
| CFO | ₹28.9 Cr | ₹53.9 Cr | ₹12.9 Cr | ₹37.1 Cr | +8.8% |
| CapEx | ₹-1.6 Cr | ₹-1.6 Cr | ₹-5.0 Cr | ₹-20.1 Cr | — |
| FCF | ₹27.2 Cr | ₹52.4 Cr | ₹7.9 Cr | ₹17.0 Cr | -14.6% |
| Total Assets | ₹347 Cr | ₹405 Cr | ₹446 Cr | ₹507 Cr | +13.4% |
| Total Debt | ₹4.2 Cr | ₹0.9 Cr | ₹2.7 Cr | ₹10.9 Cr | +37.1% |
| Shareholders' Equity | ₹214 Cr | ₹241 Cr | ₹291 Cr | ₹326 Cr | +15.1% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
ANUHPHR vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| THEMISMED THEMIS MEDICARE LTD. | -46.2% | 46 | Above Fair Value | 7.4% | — |
| SIGACHI SIGACHI INDUSTRIES LTD | +23.7% | 40 | Below Fair Value | 11.3% | — |
| WANBURY WANBURY LIMITED | -6.2% | 43 | Near Fair Value | 51.5% | — |
| AHCL ANLON HEALTHCARE LIMITED | -43.1% | 25 | Data Limited | 25.5% | — |
| AMANTA AMANTA HEALTHCARE LIMITED | -52.8% | 31 | Above Fair Value | 10.9% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for ANUHPHR in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. ANUH PHARMA LIMITED (ANUHPHR.NS) trades at 81.38 vs a model fair value of 71.10, a gap of -12.6%. Piotroski F-score: 3/9. Moat label: Mod...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of ANUHPHR →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for ANUHPHR →
Compare
Head-to-head with peers
Compare ANUHPHR side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse ANUHPHRNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.